Safety and Efficacy of NK510 to Treat NSCLC - Trial NCT06097962
Access comprehensive clinical trial information for NCT06097962 through Pure Global AI's free database. This Phase 1 trial is sponsored by Base Therapeutics (Shanghai) Co., Ltd. and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Base Therapeutics (Shanghai) Co., Ltd.
Timeline & Enrollment
Phase 1
Jul 01, 2023
Jul 01, 2024
Primary Outcome
Dose-Limiting Toxicity,Maximal Tolerable Dose
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and
 refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade.
 Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and
 EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be
 evaluated.
Data Source
ClinicalTrials.gov
NCT06097962
Non-Device Trial